Cabozantinib

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses cabozantinib, oral tablets (60 mg, 40 mg, or 20 mg). Indication: Adults with locally advanced or metastatic extrapancreatic or pancreatic neuroendocrine tumours who have received at least 1 prior therapy.